Ad
related to: t-cell cancer research- Make A Sustained Impact
Donate a small amount every month
to support ongoing cancer research.
- Ways to Give Back
Take action, give today, and
save lives. Learn more here.
- What is Immunotherapy?
Unleash the power of the immune
system to fight cancer.
- Why Donate?
We can change the way cancer is
treated and cured. Make an impact.
- Make A Sustained Impact
Search results
Results from the WOW.Com Content Network
T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. [1] Lymphoma arises mainly from the uncontrolled proliferation of lymphocytes, such as T-cells, and can become cancerous. [2] T-cell lymphoma is categorized under Non-Hodgkin lymphoma (NHL) and represents less than 15% of all Non-Hodgkin's diseases in the category. [3]
Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells [1] [2] [3] caused by human T cell leukemia/lymphotropic virus type 1 (). [4] All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. [4]
They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, (i.e., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in variable proportions. Their ...
Adoptive transfer of T cells expressing CARs is a promising anti-cancer therapeutic, because CAR-modified T cells can be engineered to target potentially any tumor associated antigen. [29] [30] Early CAR T cell research has focused on blood cancers.
Finding the factors that inhibited the immune attack on cancer has been key to developing checkpoint-blockade cancer immunotherapies. [17] In 1982, Allison first discovered the T-cell receptor. [20] Allison's research to elucidate mechanisms of T-cell responses was conducted in the 1990s at the University of California, Berkeley.
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia characterized by an aggressive malignant neoplasm of the bone marrow. [6] Acute lymphoblastic leukemia (ALL) is a condition, wherein immature white blood cells accumulate in the bone marrow and crowd out normal white blood cells. [7]
T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. [1] T-PLL is a very rare leukemia, primarily affecting adults over the age of 30.
Ad
related to: t-cell cancer research